How Ketamine Became an Antidepressant
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Topics | Esketamine Ketamine |
| Key points | Argues that ketamine catalyzed a new antidepressant paradigm, but U.S. intellectual property, regulatory, and insurance incentives—not science alone—determine who benefits and at what cost. The article synthesizes evidence across routes of administration and explains why esketamine became the only FDA-approved ketamine-based therapy for TRD. |
Abstract
Ketamine’s path from anesthetic to antidepressant reframed treatment-resistant depression (TRD) by shifting focus from monoamines to glutamate/NMDA modulation. This Article traces the science (from Yale–NIMH pilot work through Zarate 2006), synthesizes evidence across routes of administration (IV, IM, oral, sublingual, intranasal) with bioavailability tradeoffs, and explains why esketamine (Spravato) became the only FDA-approved ketamine-based therapy for TRD. It analyzes how patents, FDA approval standards (placebo vs. active comparator), DEA Schedule III controls, and payer coverage collectively shaped access, pricing, and clinical uptake—while off-label racemic ketamine and telehealth channels expanded use outside the Spravato REMS clinic model. The Article then surveys innovation pressures (startups, at-home protocols, and next-generation glutamatergic agents/HNK metabolites) and policy choices that could better align safety, evidence, and affordability. Tables summarize post-Zarate TRD outcomes and route-of-administration pharmacokinetics; another contrasts DEA scheduling for common antidepressants, situating ketamine’s unique risk/benefit profile. The takeaway: ketamine catalyzed a new antidepressant paradigm, but U.S. IP, regulatory, and insurance incentives—not science alone—determine who benefits and at what cost.